RedHill Biopharma Ltd.(RDHL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 16 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RDHL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for RedHill Biopharma Ltd. (RDHL), a Healthcare sector company. RDHL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 16 institutional filers currently hold this stock. Top institutional holders of RDHL by reported 13-F value include Yorkville Advisors Global,, GAGNON SECURITIES, CITADEL ADVISORS, based on the most recent SEC filings. RDHL trades on the Nasdaq exchange and files with the SEC under CIK 1553846. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RDHL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RedHill Biopharma Ltd. directly from SEC EDGAR.
AI Insight: RDHL Financial Trends
All eight reported periods contain no data — insufficient information to draw any financial conclusions for RDHL.
• No revenue, income, cash flow, or balance sheet figures are available across any of the eight periods examined.
⚠ Obtain actual financial disclosures before forming any view on RDHL's operating or financial trajectory.
Get alerted when RDHL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for RedHill Biopharma Ltd. including:
Top Institutional Holders of RDHL
Yorkville Advisors Global, LP
$261.5K350,870 shGAGNON SECURITIES LLC
$65.9K88,405 shCITADEL ADVISORS LLC
$15.4K20,673 shXTX Topco Ltd
$11.3K15,163 shStoneX Group Inc.
$10.8K14,481 shTWO SIGMA SECURITIES, LLC
$9.7K13,019 shGAMMA Investing LLC
$5.0K6,684 shRHUMBLINE ADVISERS
$3.8K5,116 shFederation des caisses Desjardins du Quebec
$2.5K3,388 shUBS Group AG
$615.00826 sh
| Fund | Value | Shares |
|---|---|---|
| Yorkville Advisors Global, LP | $261.5K | 350,870 |
| GAGNON SECURITIES LLC | $65.9K | 88,405 |
| CITADEL ADVISORS LLC | $15.4K | 20,673 |
| XTX Topco Ltd | $11.3K | 15,163 |
| StoneX Group Inc. | $10.8K | 14,481 |
| TWO SIGMA SECURITIES, LLC | $9.7K | 13,019 |
| GAMMA Investing LLC | $5.0K | 6,684 |
| RHUMBLINE ADVISERS | $3.8K | 5,116 |
| Federation des caisses Desjardins du Quebec | $2.5K | 3,388 |
| UBS Group AG | $615.00 | 826 |
More Healthcare Companies
View all Healthcare →Put RDHL on your watchlist
Track score changes the day RedHill Biopharma Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RDHL a good stock to buy?
13F Pro's AI-powered analysis of RedHill Biopharma Ltd. (RDHL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RDHL are available on the RDHL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own RDHL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RDHL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RedHill Biopharma Ltd.'s investment landscape.